Table 5.

Factors associated with polypharmacy (≥5 unique prescriptions) among cancer survivors (n=5,216)

	Unadjusted		Adjusteda
	PR	95% CI	PR	95% CI
Age
18–39
40–49	1.23	1.04–1.46	1.02	0.90–1.16
50–59	1.31	1.13–1.51	0.97	0.87–1.09
60–69	1.63	1.40–1.88	1.04	0.93–1.16
70–79	1.74	1.51–2.01	1.04	0.93–1.17
≥80	1.89	1.63–2.20	1.05	0.93–1.19
Female sex	1.01	0.96–1.07	1.06	1.01–1.10
Race/ethnicity
Non-Hispanic white
Non-Hispanic black	0.98	0.92–1.04	0.93	0.88–0.98
Hispanic	0.81	0.74–0.89	0.94	0.88–1.01
Other	0.83	0.74–0.94	0.89	0.81–0.99
Marital status
Married
Not married	1.06	1.01–1.12	0.97	0.94–1.00
Education
Less than high school	1.13	1.07–1.20	0.99	0.95–1.03
High school degree or some college
College degree or higher	0.98	0.92–1.04	1.00	0.96–1.05
Employment status
Employed
Unemployed	0.68	0.64–0.73	0.90	0.85–0.95
Insurance
Private
Medicaid (any) and other public	1.21	1.15–1.29	1.00	0.95–1.04
Medicare (only)	1.18	1.10–1.26	0.96	0.92–1.01
Uninsured (only)	0.67	0.55–0.82	0.81	0.70–0.95
Health indicators
Comorbidity Count
0
1	1.53	1.26–1.87	1.46	1.21–1.77
2+	2.94	2.51–3.45	2.48	2.11–2.90
Physical limitations	1.51	1.44–1.58	1.15	1.10–1.21
Health status
Excellent/very good
Good	1.17	1.10–1.25	1.16	1.10–1.22
Fair/poor	1.31	1.23–1.40	1.16	1.09–1.22
Time since diagnosis
≤1 year	1.08	0.99–1.17
2–5 years
>5 years	1.02	0.95–1.10

Abbreviations: PR, prevalence ratio; CI, confidence interval

^aAdjusted for age, race/ethnicity, education, insurance, comorbidity count, physical limitations, and health status; adjusted analysis on 5,167 respondents